CHO Pharma, Inc. (TPEX:6586)
Taiwan · Delayed Price · Currency is TWD 110.50
-1.50 (-1.34%)
Aug 26, 2026, 1:54 PM CST
CHO Pharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.71 | 1.43 | 3.58 | - | 0.06 | 3.57 | |
Revenue Growth | -46.88% | -60.03% | - | - | -98.32% | 2486.96% |
Cost of Revenue | 0.56 | 0.37 | 1.87 | - | 0 | 0.21 |
Gross Profit | 1.15 | 1.07 | 1.71 | - | 0.06 | 3.36 |
Selling, General & Admin | 38.1 | 40.06 | 31.93 | 29.61 | 24.86 | 20.35 |
Research & Development | 264.74 | 286.85 | 219.08 | 239.39 | 326.1 | 193.51 |
Operating Expenses | 302.84 | 326.91 | 251 | 269 | 350.96 | 213.85 |
Operating Income | -301.69 | -325.84 | -249.29 | -269 | -350.9 | -210.49 |
Interest Expense | -0.27 | -0.41 | -0.68 | -0.08 | -0.3 | -0.58 |
Interest & Investment Income | 34.19 | 36.26 | 37.68 | 16.24 | 7.05 | 5.46 |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | 0.07 | -0.53 | -0.13 | 0.22 |
Other Non Operating Income (Expenses) | -0.25 | - | - | 0.01 | 5.88 | 5.46 |
EBT Excluding Unusual Items | -268.04 | -290.01 | -212.23 | -253.36 | -338.39 | -199.93 |
Asset Writedown | - | - | - | -52.73 | - | -6 |
Pretax Income | -268.04 | -290.01 | -212.23 | -306.09 | -338.39 | -205.93 |
Net Income | -268.04 | -290.01 | -212.23 | -306.09 | -338.39 | -205.93 |
Net Income to Common | -268.04 | -290.01 | -212.23 | -306.09 | -338.39 | -205.93 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 213 | 214 | 214 | 191 | 184 | 184 |
Shares Outstanding (Diluted) | 213 | 214 | 214 | 191 | 184 | 184 |
Shares Change | -0.43% | - | 11.86% | 4.00% | 0.04% | 0.12% |
EPS (Basic) | -1.26 | -1.36 | -0.99 | -1.60 | -1.84 | -1.12 |
EPS (Diluted) | -1.26 | -1.36 | -0.99 | -1.60 | -1.84 | -1.12 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -249.78 | -288.87 | -222.87 | -293.13 | -258.9 | -196.11 |
Free Cash Flow Per Share | -1.17 | -1.35 | -1.04 | -1.53 | -1.41 | -1.07 |
Gross Margin | 67.45% | 74.49% | 47.77% | - | 98.33% | 94.09% |
Operating Margin | -17694.31% | -22770.16% | -6963.49% | - | -584833.33% | -5896.11% |
Profit Margin | -15720.88% | -20265.97% | -5928.10% | - | -563988.33% | -5768.21% |
Free Cash Flow Margin | -14649.80% | -20186.58% | -6225.53% | - | -431501.67% | -5493.25% |
EBITDA | -292.21 | -313.46 | -237.71 | -250.3 | -324.67 | -184.88 |
D&A For EBITDA | 9.48 | 12.38 | 11.59 | 18.7 | 26.23 | 25.61 |
EBIT | -301.69 | -325.84 | -249.29 | -269 | -350.9 | -210.49 |